Daraxonrasib Approved: What Oncology Nurses Must Know About Rasonque

The US Food and Drug Administration (FDA) has approved daraxonrasib (Rasonque; Revolution Medicines, Inc.) once-daily oral tablets. This first-in-class, broad-spectrum RAS(ON) multi-selective inhibitor is the first targeted therapy approved to directly inhibit RAS proteins—the key growth driver in more than 90% of pancreatic ductal adenocarcinoma (PDAC) cases.